Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma
- 1 March 2006
- journal article
- immunotherapy
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (7), 1169-1177
- https://doi.org/10.1200/jco.2005.03.6830
Abstract
Purpose To characterize the number and functional status of CD4+CD25+ regulatory T cells (Tregs) in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) treated with high-dose bolu...Keywords
This publication has 40 references indexed in Scilit:
- Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast AdenocarcinomaPublished by The American Association of Immunologists ,2002
- CD4+CD25+ suppressor T cells: more questions than answersNature Reviews Immunology, 2002
- Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell ProliferationPublished by The American Association of Immunologists ,2002
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Biology of the Interleukin-2 ReceptorAdvances in Immunology, 1998
- Generalized autoimmune disease in interleukin‐2‐deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cellsEuropean Journal of Immunology, 1995
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.Journal of Clinical Oncology, 1995
- Development and proliferation of lymphocytes in mice deficient for both interleukins‐2 and ‐4European Journal of Immunology, 1994
- Ulcerative colitis-like disease in mice with a disrupted interleukin-2 geneCell, 1993
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988